research Minoxidil for severe hypertension after failure of other hypotensive drugs.
Minoxidil effectively controls blood pressure in severe cases, but has serious side effects and causes hair growth in women.
Search
for
Sort by
Research
90-120 / 1000+ results 
research Ritlecitinib: First Approval
Ritlecitinib is approved in the USA and Japan for treating severe hair loss in people aged 12 and older.
research Clinical Aspects and Spectrum of Illness of TSS: Overview
Toxic Shock Syndrome progresses quickly, often involves multiple organs, and is linked to Staphylococcus aureus toxins, with treatment options available but diagnostic challenges remaining.
research Efficacy and safety of the oral Janus kinase inhibitor baricitinib in the treatment of adults with alopecia areata: Phase 2 results from a randomized controlled study
Baricitinib is effective and safe for treating severe alopecia areata.
research THE DISEASE SPECTRUM, EPIDEMIOLOGY, AND ETIOLOGY OF TOXIC-SHOCK SYNDROME
Toxic Shock Syndrome cases increased due to new factors, but decreased with public health measures and changes in tampon use.
research Interventions for nail psoriasis
Some systemic treatments work for nail psoriasis but can have serious side effects.
research Topical Janus kinase inhibitors: A review of applications in dermatology
Topical JAK inhibitors may help treat some skin conditions but need more research.
research Use of topical minoxidil in the treatment of male pattern baldness
Minoxidil effectively regrows hair in male pattern baldness.
research The Pharmacologic Treatment of Muscle Pain
The document concludes that more research is needed to understand how to treat muscle pain with drugs.
research Baricitinib: From Rheumatoid Arthritis to COVID‐19
Baricitinib helps treat several diseases, including COVID-19, but has side effects and needs careful monitoring.
research Avaliação dos efeitos adversos clínicos e alterações laboratoriais em pacientes com acne vulgar tratados com isotretinoína oral
Isotretinoin is safe and effective for acne, with common side effects like dry lips; serious side effects are rare.
research Consensus on the use of oral isotretinoin in dermatology - Brazilian Society of Dermatology
The Brazilian Society of Dermatology agrees that oral isotretinoin is effective for acne and other skin conditions, and it's safe when monitored, but more research is needed on dosing and duration.
research 17β-Estradiol Enhances Vascular Endothelial Growth Factor Production and Dihydrotestosterone Antagonizes the Enhancement via the Regulation of Adenylate Cyclase in Differentiated THP-1 Cells
Estrogen increases blood vessel growth factor production, while testosterone blocks this increase.
research Comparative Efficacy and Safety of Janus Kinase Inhibitors Used in Alopecia Areata: A Systematic Review and Meta-analysis
Baricitinib and deuruxolitinib are effective for treating alopecia areata, but their efficacy depends on the dose.
research Indirect clinical markers for the detection of anabolic steroid abuse beyond the conventional doping control in athletes
New signs like changes in blood markers, physical symptoms, and behavioral shifts may help detect hidden steroid use in athletes.
research Acute diffuse and total alopecia of the female scalp associated with borrelia-infection
A woman's total hair loss was linked to a Borrelia infection and was reversed with appropriate treatment.
research Significance of iron status in hair loss in women
Iron deficiency might contribute to hair loss in women.
research Safety of Janus Kinase inhibitors in Patients with Alopecia Areata: A Systematic Review
JAK inhibitors for alopecia areata are linked to minor side effects like headache and acne, but not to an increased risk of serious adverse events.
research Upadacitinib Therapy in Adolescent Severe Alopecia Areata: A Case Series and Narrative Review
Upadacitinib is effective and safe for treating severe Alopecia Areata in adolescents.
research Treatments for Moderate-to-Severe Alopecia Areata: A Systematic Narrative Review
Some treatments for severe hair loss work but often have side effects, with baricitinib showing the most promise.
research Janus Kinase inhibitors in dermatology: a review
JAK inhibitors effectively treat skin conditions and topical forms are safer.
research Efficacy, Safety, and Tolerability of Upadacitinib in Adults and Adolescents With Severe Alopecia Areata: Results From the Randomized, Placebo-Controlled, Double-Blind Phase 3 Program (UP-AA)
Upadacitinib effectively treats severe alopecia areata and is safe.
research Baricitinib Provides Significant Hair Regrowth In Adolescents With Severe Alopecia Areata: 52-Week Efficacy and Safety Results From A Phase 3 Randomized, Controlled Trial
Baricitinib significantly regrows hair in teens with severe alopecia areata.
research The Burden of Alopecia Areata and Management with Baricitinib in the United Arab Emirates: A Narrative Review
Baricitinib is a promising treatment for alopecia areata in the UAE, but there are challenges with data and access.
research Updated Integrated Safety Analysis of Ritlecitinib Over 72 Months In Patients With Alopecia Areata From the ALLEGRO Clinical Trial Program
Ritlecitinib is generally safe for alopecia areata patients over 72 months.
research Treatment of alopecia areata with JAK inhibitors: a review of the literature
JAK inhibitors can help regrow hair in alopecia areata but have potential long-term risks and require careful monitoring.
research Secondary Adrenal Insufficiency : A Case Report
A man's health improved after treating his undiagnosed adrenal insufficiency, which caused fatigue and weight loss.
research Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program
Ritlecitinib is safe and well-tolerated for treating alopecia areata in patients aged 12 and older.
research Assessment of Multidimensional Health Care Parameters Among Adults in Japan for Developing a Virtual Human Generative Model: Protocol for a Cross-sectional Study (Preprint)
The study aims to create a model to improve personalized and preventive health care.
research Reporting on Adverse Clinical Events
The FDA warned about safety issues with remdesivir and tofacitinib, finasteride is linked to suicidality, potent topical corticosteroids increase osteoporosis risk, henna can cause hemolysis in G6PD deficiency, chemotherapeutic agents can cause adverse reactions, drug interactions are common in cancer patients, ketamine can reduce at-risk drinking, high dose of anticholinergics increases dementia risk in Parkinson's patients, and prenatal exposure to second-generation antipsychotics increases pregnancy complications.